Home › Angioedema › NCT06818474
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
RecruitingPhase 4
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance) * historical attack rate of \>= on attack per month prior to starting tranexamic acid (TAA) Exclusion Criteria: * History of anaphylaxis or hypersensitivity to biologics * History of major systemic disease not well controlled in opinion of the PI * Women who are pregnant or breast feeding * Concurrent participation in other clinical trials * HAE Type 1 or 2 and normal complement HAE
About the study
use of lanadelumab in patients with acquired angioedema
What is being tested
- Lanadelumab 300 mg (biological)
Sponsor: Bernstein Clinical Research Center · Participants: 5 · Started: Jun 1, 2024
Contact the study team
- Karen Berendts · Phone: 513-354-1746
Official record on ClinicalTrials.gov — NCT06818474
Locations in the U.S.
| Ohio | Bernstein Clinical Research Center, LLC, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.